Butanoic acid, 4-(triphenylphosphoranylidene)- | 52134-55-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Butanoic acid, 4-(triphenylphosphoranylidene)-
• 英文别名: 4-(triphenyl-λ5-phosphanylidene)butanoic acid
• CAS: 52134-55-1
• 化学式: C₂₂H₂₁O₂P
• 分子量: 348.381
• InChiKey: GNYXGTLLHAESOB-UHFFFAOYSA-N

物化性质

• 沸点：
  550.1±52.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tetrahydro-2H-2-pyranol 、 Butanoic acid, 4-(triphenylphosphoranylidene)- 以 四氢呋喃 、 甲苯 为溶剂， 以0.346 g的产率得到9-羟基壬-4-烯酸
  参考文献：
  名称：

  O'Hanlon, Peter J.; Rogers, Norman H.; Tyler, John W., Journal of the Chemical Society. Perkin transactions I, 1983, # 11, p. 2655 - 2657

  摘要：

  DOI：
• 作为产物：
  描述：

  (3-丙羧基)三苯基溴化膦 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 Butanoic acid, 4-(triphenylphosphoranylidene)-
  参考文献：
  名称：

  Synthesis of chiral vinylglycines

  摘要：

  (R)- or (S)-benzyl 4-formyl-2,2-dimethyl-3-oxazolidinecarboxylate (7a) and (R)- or (S)-1,1-dimethylethyl 4-formyl-2,2-dimethyl-3-oxazolidinecarboxylate (7b), readily available from serine, react with Wittig reagents to give alkenes 8. Selective deprotection followed by oxidation of the resulting unsaturated amino alcohols 9 provides vinylglycines 5 of defined configuration (> 95% ee) and double-bond geometry. D-Vinylglycines are obtained from L-serine, and conversely, D-serine gives beta,gamma-unsaturated amino acids with the L configuration. The double-bond geometry is controlled by the nature of the phosphorous ylide employed. The scope and limitations of this new methodology for the preparation of chiral vinylglycines is examined.

  DOI：

  10.1021/jo00013a023

文献信息

• VLA-4 inhibitor compounds
  申请人：Daiichi Pharmaceutical Co., LTD.

  公开号：US20030078249A1

  公开（公告）日：2003-04-24

  Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: 1 As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.

  本发明公开了选择性抑制配体与α4β1整合素（VLA-4）结合的化合物及其制备方法。在一个实施例中，本发明的化合物由式I表示： 1 作为VLA-4介导的细胞粘附的选择性抑制剂，本发明的化合物可用于治疗与该粘附相关的疾病，包括但不限于炎症和自身免疫反应、糖尿病、哮喘、银屑病、炎症性肠病、移植排斥和肿瘤转移。还公开了包含式I化合物的药物组合物、抑制VLA-4介导的细胞粘附的方法以及治疗与VLA-4介导的细胞粘附相关疾病的方法。
• BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE
  申请人：Venkatesan Aranapakam Mudumbai

  公开号：US20090054454A1

  公开（公告）日：2009-02-26

  Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed.

  本专利揭示了苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物以及含有这些化合物的组合物。还揭示了使用苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物以及含有这种组合物在治疗和/或预防与5-羟色胺相关的疾病，如抑郁症和焦虑症的方法。此外，还揭示了制备苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物的方法。
• Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use
  申请人：Venkatesan Mudumbai Aranapakam

  公开号：US20050004162A1

  公开（公告）日：2005-01-06

  3-Piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed. Methods of using the derivatives and compositions containing the derivatives in the prevention and/or treatment of serotonin disorders, such as depression and anxiety, are also disclosed. Additionally, processes for the preparation of 3-piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed.

  3-哌啶基-1H-吲哚和3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚衍生物已被披露。还披露了使用这些衍生物以及含有这些衍生物的组合物在预防和/或治疗血清素紊乱，如抑郁症和焦虑症方面的方法。此外，还披露了制备3-哌啶基-1H-吲哚和3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚衍生物的方法。
• Leukotriene receptor antagonists. 4. Synthesis and leukotriene D4/E4 receptor antagonist activity of 4-(alkyl)acetophenone derivatives
  作者：D. Mark Gapinski、Carlos R. Roman、Lynn E. Rinkema、Jerome H. Fleisch

  DOI：10.1021/jm00396a027

  日期：1988.1

  Analogues of the leukotriene D4/E4 receptor antagonist LY171883 (1a) were synthesized in which the tetrazole was linked to the hydroxyacetophenone moiety by an all-methylene carbon chain. A key step in the synthesis involved a Wittig olefin-forming reaction between 3-methoxy-2-propylbenzaldehyde and the ylide derived from (4-carboxybutyl)triphenylphosphonium bromide to form the desired carbon chain

  合成了白三烯D4 / E4受体拮抗剂LY171883（1a）的类似物，其中四唑通过全亚甲基碳链连接到羟基苯乙酮部分。合成中的关键步骤涉及3-甲氧基-2-丙基苯甲醛与衍生自（4-羧基丁基）三苯基溴化的内鎓盐之间形成Wittig烯烃的反应，以形成所需的碳链。使用区域选择性的弗里斯重排来形成邻羟基苯乙酮。将四唑与苯乙酮被四个和五个亚甲基隔开的化合物与相应的衍生物进行了比较，在该衍生物中，氧原子将四唑链连接到芳环上，具有拮抗LTD4-或LTE4诱导的分离物收缩的能力。豚鼠回肠。与1a相比，“ carba” 类似物7a显示出几乎相同的LTD4拮抗剂活性。这两种化合物的LTE4拮抗剂活性也相同。在较短的链系列中，“ carba”类似物7b显示出增强的LTD4拮抗剂活性，而LTE4拮抗剂活性则高出约10倍。这些结果表明，与豚鼠回肠中的LTD4或LTE4受体位点缔合时，对位于1a和1b乙酰基的氧原子不是很重要。
• Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use
  申请人：Venkatesan Mudumbai Aranapakam

  公开号：US20050059673A1

  公开（公告）日：2005-03-17

  Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed.

  本发明涉及苯并呋喃基-和苯并噻吩基-哌嗪基喹啉衍生物及含有该类化合物的组合物。本发明还涉及使用苯并呋喃基-和苯并噻吩基-哌嗪基喹啉衍生物及含有该类组合物治疗和/或预防与血清素相关的疾病，例如抑郁和焦虑。此外，还公开了制备苯并呋喃基-和苯并噻吩基-哌嗪基喹啉衍生物的方法。